193 related articles for article (PubMed ID: 23492364)
21. Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.
Carra E; Barbieri F; Marubbi D; Pattarozzi A; Favoni RE; Florio T; Daga A
Cell Cycle; 2013 Feb; 12(3):491-500. PubMed ID: 23324350
[TBL] [Abstract][Full Text] [Related]
22. Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas.
Kosty J; Lu F; Kupp R; Mehta S; Lu QR
Cell Cycle; 2017 Sep; 16(18):1654-1660. PubMed ID: 28806136
[TBL] [Abstract][Full Text] [Related]
23. Hsp90 inhibitor HSP990 in very low dose upregulates EAAT2 and exerts potent antiepileptic activity.
Sha L; Chen T; Deng Y; Du T; Ma K; Zhu W; Shen Y; Xu Q
Theranostics; 2020; 10(18):8415-8429. PubMed ID: 32724478
[No Abstract] [Full Text] [Related]
24. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
[TBL] [Abstract][Full Text] [Related]
25. The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme.
Zhu H; Woolfenden S; Bronson RT; Jaffer ZM; Barluenga S; Winssinger N; Rubenstein AE; Chen R; Charest A
Mol Cancer Ther; 2010 Sep; 9(9):2618-26. PubMed ID: 20643786
[TBL] [Abstract][Full Text] [Related]
26. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma.
Gaspar N; Sharp SY; Eccles SA; Gowan S; Popov S; Jones C; Pearson A; Vassal G; Workman P
Mol Cancer Ther; 2010 May; 9(5):1219-33. PubMed ID: 20457619
[TBL] [Abstract][Full Text] [Related]
27. Phostine PST3.1a Targets MGAT5 and Inhibits Glioblastoma-Initiating Cell Invasiveness and Proliferation.
Hassani Z; Saleh A; Turpault S; Khiati S; Morelle W; Vignon J; Hugnot JP; Uro-Coste E; Legrand P; Delaforge M; Loiseau S; Clarion L; Lecouvey M; Volle JN; Virieux D; Pirat JL; Duffau H; Bakalara N
Mol Cancer Res; 2017 Oct; 15(10):1376-1387. PubMed ID: 28634226
[TBL] [Abstract][Full Text] [Related]
28. Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer.
Su YH; Tang WC; Cheng YW; Sia P; Huang CC; Lee YC; Jiang HY; Wu MH; Lai IL; Lee JW; Lee KH
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2261-72. PubMed ID: 25982393
[TBL] [Abstract][Full Text] [Related]
29. Retraction: Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig 2-positive glioma tumor-initiating cells.
Koul D; Yao J; Wan S; Yuan Y; Sulman E; Lang F; Yung WK; Colman H
Cancer Res; 2014 Nov; 74(22):6731-2. PubMed ID: 25398854
[No Abstract] [Full Text] [Related]
30. Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells.
Morris-Hanon O; Marazita MC; Romorini L; Isaja L; Fernandez-Espinosa DD; Sevlever GE; Scassa ME; Videla-Richardson GA
Mol Neurobiol; 2019 Nov; 56(11):7810-7821. PubMed ID: 31124078
[TBL] [Abstract][Full Text] [Related]
31. The NF-κB RelB protein is an oncogenic driver of mesenchymal glioma.
Lee DW; Ramakrishnan D; Valenta J; Parney IF; Bayless KJ; Sitcheran R
PLoS One; 2013; 8(2):e57489. PubMed ID: 23451236
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and Evaluation of the Tumor Cell Growth Inhibitory Potential of New Putative HSP90 Inhibitors.
Bizarro A; Sousa D; Lima RT; Musso L; Cincinelli R; Zuco V; De Cesare M; Dallavalle S; Vasconcelos MH
Molecules; 2018 Feb; 23(2):. PubMed ID: 29438315
[TBL] [Abstract][Full Text] [Related]
33. Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia.
Djuzenova CS; Blassl C; Roloff K; Kuger S; Katzer A; Niewidok N; Günther N; Polat B; Sukhorukov VL; Flentje M
Cancer Biol Ther; 2012 Apr; 13(6):425-34. PubMed ID: 22286776
[TBL] [Abstract][Full Text] [Related]
34. NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro.
Wang WJ; Long LM; Yang N; Zhang QQ; Ji WJ; Zhao JH; Qin ZH; Wang Z; Chen G; Liang ZQ
Acta Pharmacol Sin; 2013 May; 34(5):681-90. PubMed ID: 23603977
[TBL] [Abstract][Full Text] [Related]
35. Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines.
Premkumar DR; Jane EP; Pollack IF
Int J Oncol; 2010 Sep; 37(3):633-43. PubMed ID: 20664932
[TBL] [Abstract][Full Text] [Related]
36. Tyrosine kinase Eph receptor A6 sensitizes glioma-initiating cells towards bone morphogenetic protein-induced apoptosis.
Raja E; Morikawa M; Nishida J; Tanabe R; Takahashi K; Seeherman HJ; Saito N; Todo T; Miyazono K
Cancer Sci; 2019 Nov; 110(11):3486-3496. PubMed ID: 31483918
[TBL] [Abstract][Full Text] [Related]
37. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
38. 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells.
Satriyo PB; Su CM; Ong JR; Huang WC; Fong IH; Lin CC; Aryandono T; Haryana SM; Deng L; Huang CC; Tzeng YM; Chao TY; Liu HW; Yeh CT
Toxicol Appl Pharmacol; 2021 Jul; 422():115493. PubMed ID: 33727089
[TBL] [Abstract][Full Text] [Related]
39. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M
Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106
[TBL] [Abstract][Full Text] [Related]
40. Targeting the bHLH transcriptional networks by mutated E proteins in experimental glioma.
Beyeler S; Joly S; Fries M; Obermair FJ; Burn F; Mehmood R; Tabatabai G; Raineteau O
Stem Cells; 2014 Oct; 32(10):2583-95. PubMed ID: 24965159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
